Can You Take Beta Blockers Like Metoprolol Alongside Ketamine or Spravato Treatment?
Yes, if you are considering new psychiatric options, you can often safely continue beta blockers during ketamine therapy (an evidence-based, off-label application of a medicine that’s been in use for over 50 years) or Spravato (FDA-approved for adults with treatment-resistant depression and major depression with suicidal thoughts). However, because both beta blockers and ketamine-class medicines affect cardiovascular function, careful medical evaluation and real-time vital sign monitoring are essential before and during every session.
This is a question we hear frequently at Lumin Health – and it matters more than most people realize. If you are managing high blood pressure, anxiety, performance-related stress, or a cardiac condition with a beta blocker, and you are also exploring ketamine or esketamine treatment for treatment-resistant depression, the pharmacological intersection of these two medication classes deserves a far more nuanced conversation than the one most resources provide.
Why the Beta Blockers Conversation Comes Up So Often in Depression Care
Beta blockers like metoprolol, propranolol, and atenolol (to name a few), are commonly prescribed. Originally developed for hypertension and cardiac arrhythmias, they are now widely used off-label for situational anxiety, high-blood pressure, migraine prevention, and the somatic symptoms of panic. In our practice, many people presenting for an evaluation regarding ketamine for depression are already taking metoprolol or a related beta-1 selective antagonist.
The overlap is not coincidental. If you are managing treatment-resistant depression, you might also carry comorbid anxiety disorders, autonomic dysregulation, or cardiovascular conditions that have already led a prior provider to prescribe a beta blocker. When you have cycled through multiple SSRIs and SNRIs without adequate response, the medication list you bring to your first evaluation is rarely short.
What requires careful attention is not the existence of the overlap. It is ensuring that the pharmacodynamic interaction between beta blockers and glutamate-modulating agents is discussed with you in meaningful depth.
The Cardiovascular Crossroads – What Beta Blockers Do and Why It Matters During Treatment
Beta blockers by modulating the impact of a chemical called norepinephrine on set of particular receptors called beta-1 adrenergic receptors in the heart, reducing heart rate, contractility, and blood pressure. It dampens the sympathetic "fight or flight" response at the cardiac level. This is precisely why it feels calming – it blunts the physical acceleration that accompanies anxiety and stress. Some of the medications that belong to this class, such as propranolol, also cross the blood brain barrier and modulate a similar set of receptors in the brain.
Ketamine and Spravato (esketamine), by contrast, tend to produce transient sympathomimetic effects (temporary stimulations of the sympathetic nervous system). It helps to understand the difference at a molecular level. Off-label ketamine is a racemic mixture containing both the S-ketamine and R-ketamine molecules. Spravato is the S-enantiomer (the 's' stands for sinistrum, Latin for 'left', as the esketamine molecule is oriented to the left), which is the more active component. During a session with either medication, it is common to observe modest increases in heart rate, blood pressure, and sometimes cardiac output (the sympathomimetic effects alluded to, above). These effects are typically self-limiting, peaking within 20 to 40 minutes and resolving without intervention. But they are real, measurable, and clinically relevant – especially if your cardiovascular baseline is already being pharmacologically managed.
The critical insight is this: metoprolol and ketamine push the cardiovascular system in opposing directions. Metoprolol suppresses sympathetic drive. Ketamine transiently activates it. For many people, this creates a blunting effect – the metoprolol partially attenuates the cardiovascular response to ketamine, which can actually be protective. But if you are on higher doses of beta blockers or have underlying conduction abnormalities, the interaction requires closer monitoring.
A 2019 analysis published in the Journal of Clinical Psychopharmacology confirmed that transient blood pressure elevations during ketamine administration are among the most common acute effects, reinforcing the importance of pre-treatment cardiovascular screening for anyone with an existing cardiac medication regimen.
How We Evaluate This at Lumin Health – A Step-by-Step Clinical Process
At Lumin Health, we do not treat your medication list in isolation. We evaluate your entire profile – your cardiac history, your current dosing, your autonomic profile, and your psychiatric trajectory. Here is how that process unfolds:
- During your initial evaluation, we review all medications, documenting the specific beta blocker, dose, and indication (cardiac vs. psychiatric vs. both).
- We assess your resting vital signs – including: heart rate, blood pressure, and oxygen saturation – to establish a pre-treatment cardiovascular baseline while on metoprolol.
- We develop an individualized monitoring protocol. If you are taking a beta blocker, this may typically includes more frequent intra-session vital sign checks to make sure you’re doing well.
- During intramuscular (IM) ketamine injection sessions, we observe the interplay between a beta blocker’s suppressive cardiovascular effects and ketamine's transient sympathomimetic response in real time, adjusting the clinical environment and dosing accordingly.
- For Spravato sessions – which carry their own FDA-mandated two-hour monitoring requirement – we layer as needed additional cardiovascular vigilance on top of the standard REMS protocol if you are taking beta blockers.
- Post-session, we document your cardiovascular response profile and use it to inform dosing and monitoring decisions for subsequent sessions.
This is not a checkbox exercise. It is a dynamic, session-by-session calibration that reflects the reality of helping individuals navigate multiple medication interactions safely.
The Deeper Question – Why Depression and Cardiac Medication So Often Travel Together
There is a neurobiological reason that depression, anxiety, and cardiovascular dysregulation can cluster in the same individuals, and understanding it is essential to understanding why these treatments can be particularly relevant.
Your brain isn't broken – it may be stuck. The Default Mode Network (DMN) – the brain's internally focused, self-referential network – becomes overactive and inflexible in treatment-resistant depression. Thought patterns become entrained. Rumination deepens. Hopelessness becomes neurologically encoded. And critically, the autonomic nervous system becomes locked in a chronic stress posture. Reward circuits skew toward futility.
This is where the mechanism of ketamine therapy becomes clinically compelling. Ketamine modulates glutamate signaling, promotes the release of brain-derived neurotrophic factor (BDNF – a protein that supports the growth and survival of neurons), and creates a window of enhanced neuroplasticity – the brain's capacity to form new connections and pathways. Within that window, the rigid patterns that drive both depressive cognition and autonomic hyperactivation become more amenable to change.
A landmark 2019 study in the American Journal of Psychiatry demonstrated that ketamine's rapid antidepressant effects are mediated in part through glutamate-driven synaptogenesis (the formation of new synaptic connections) in the prefrontal cortex – the very region responsible for top-down regulation of both mood and autonomic function.
"When someone comes to us on a beta blocker and two or three failed antidepressants, I don't necessarily see two separate problems. I see one system – neural, autonomic, cardiovascular – that has become stuck. The beta blocker is managing a downstream symptom. Our work with ketamine therapy or Spravato aims to address the upstream rigidity that may be driving all of it. The person's own capacity for change, their self-guided intent, is what ultimately makes the difference. We are creating a biologically receptive window – they are the ones who walk through it."
— Dr. Ben Yudkoff, Chief Medical Officer at Lumin Health
What You Should Know Before Starting Ketamine or Esketamine on Metoprolol
If you are currently taking metoprolol or another beta blocker and considering ketamine therapy or Spravato, here are the clinical realities we want you to understand:
- Do not change how you take the beta blocker - there is no need to do so and doing so can cause complications, which would complicate – not simplify – your treatment course.
- Beta blockers absolutely do not disqualify you from ketamine therapy or Spravato. In most cases, the combination is manageable with appropriate monitoring.
- You will need to arrange a ride home after every session – this is a safety requirement regardless of your medication profile, but it is particularly important when cardiovascular medications are in play.
- Lumin Health provides Intramuscular (IM) ketamine injections, which offer a controlled, efficient delivery with a predictable pharmacokinetic profile. This provides meaningful benefits, such as speed and comfort compared to a slow IV infusion, making it an important consideration when managing medication interactions.
The Role of Psychotherapy When Managing Multiple Medications
Navigating both cardiac medications and psychiatric treatment cancarry its own burden. The medication management alone can feel overwhelming – timing doses, tracking side effects, coordinating between providers. This is where support can become helpful.
At Lumin Health, the behavioral support that accompanies ketamine therapy and Spravato sessions is designed to help you process your experience, track your trajectory, and leverage the neuroplastic window that treatment creates. Your brain is not broken – it may be stuck. The medications create biological opportunity. Your self-guided intent, your willingness to engage with the process, and your own intuition about what needs to shift are what drive lasting change.
Some people also choose to work with outside therapists independently, which can complement the biological work. But the foundation of what we do at Lumin Health is psychiatrist-led, medically rigorous, and grounded in the pharmacological expertise required to safely manage complex medication profiles like the one we are discussing here.
Frequently Asked Questions About Beta Blockers, Metoprolol, and Ketamine-Class Treatments
Will beta blockers, like metoprolol reduce the effectiveness of ketamine or esketamine?
There is no established evidence that beta blockers diminish the antidepressant efficacy of ketamine or esketamine. The glutamate-modulating mechanism through which ketamine and esketamine treatments work operates independently of beta-adrenergic blockade. Some individuals even report that the cardiovascular blunting from beta blockers makes the transient physical sensations during treatment more manageable, in fact.
Should I take my beta blocker on the day of a Spravato session?
In most cases, yes. We generally recommend maintaining your regular medication schedule unless your provider at Lumin Health gives you specific, individualized guidance otherwise. Skipping a dose of a beta blocker like metoprolol on treatment day can introduce cardiovascular unpredictability that complicates monitoring. This is evaluated on a case-by-case basis during your evaluation.
Is the cardiovascular monitoring different if I am on a beta blocker?
Not necessarily. For some, based on clinical need, we may decided to include more frequent blood pressure and heart rate assessments, but most people are monitored with a regular treatment monitoring plan.
Can beta blockers mask warning signs during a session?
Rarely. At times, we notice that an increased blood pressure correlates with increased anxiety during a treatment experience. That said, we also have open lines of communication with patients receiving care at Lumin Health and rely on self reports even more than blood pressures. This is largely not a concern.
Exploring Whether This May Be a Fit
If you are taking a beta blocker and have found that conventional antidepressants have not provided adequate relief, meaningful relief may still be possible. The intersection of cardiac medication management and advanced psychiatric treatment is complex, but it is precisely the kind of clinical complexity that Lumin Health was built to navigate.
We are a psychiatrist-led practice with academically-affiliated leadership, based out of the Boston Metro area and expanding to other states. While we serve our local community, we hope the clinical depth of this discussion offers value to anyone – anywhere – trying to understand whether their current medication profile is compatible with newer approaches to treatment-resistant depression.
If you are exploring whether ketamine therapy or Spravato might be appropriate alongside your current cardiac medications, we would be grateful to walk with you toward relief. You can reach our clinical team to discuss your specific situation and evaluate whether this may be a fit for your needs.
